Jeffrey Girshman

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

Adam J. Schoenfeld, Kathryn C. Arbour, Hira Rizvi et al. · Annals of Oncology · 2019 · 401 citations · Full text

Clinical Immunology, Autoimmune Disease, Immunology +9

Membrane Stiffness and Channel Function

Jens A. Lundbæk, P. Birn, Jeffrey Girshman et al. · Biochemistry · 1996 · 312 citations

Membrane Structure, Proteinlipid Interaction, Shifts Channel Inactivation +19

Regulation of Sodium Channel Function by Bilayer Elasticity

Jens A. Lundbæk, P. Birn, Anker Jón Hansen et al. · The Journal of General Physiology · 2004 · 263 citations · Full text

CT-Guided Percutaneous Catheter Drainage of Acute Necrotizing Pancreatitis: Clinical Experience and Observations in Patients with Sterile and Infected Necrosis

Koenraad J. Mortelé, Jeffrey Girshman, Dênis Szejnfeld et al. · American Journal of Roentgenology · 2008 · 126 citations

Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non–Small-Cell Lung Cancer

Natalie I. Vokes, David Liu, Biagio Ricciuti et al. · JCO Precision Oncology · 2019 · 119 citations · Full text